Genomic Testing

Questions discussed in this category

For patients with resected colon cancer, to what extent would you adapt adjuvant chemotherapy if ctDNA results don't correspond with your initial treatment recommendation?

5 Answers available

When do you recommend incorporating HER2 testing into the diagnostic pathway for tumor types where HER2 overexpression is not commonly assessed?

Will you test HER2 IHC upfront for all? Or wait until later in the disease course, once a patient has exhausted other standard of care options?

3 Answers available

How, if at all, are you employing ctDNA in the management of patients with colon cancer?

3 Answers available

Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?

Assuming no other actionable mutations.

3 Answers available

Are you planning to start running IHC HER2 testing on all tumor types, even those where HER2 overexpression is less typical, in light of tumor agnostic approval of trastuzumab deruxtecan?

Or can we rely on NGS testing to determine eligible patients?

2 Answers available

Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

1 Answer available

Does cytotoxic chemotherapy affect the yield of germline testing?

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

1 Answer available

Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?

1 Answer available

Can you use NGS panels or ctDNA to help you find organ of origin in the workup of carcinoma of unknown origin?

If so, what alterations would be helpful to narrow the diagnosis?

1 Answer available

How do you envision genomic scoring systems for pediatric cancers being applied in a real-world setting?

Such as the scoring system described by Summers et al, "Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact...

2 Answers available

Do you feel that more frequent genomic sequencing will be cost-effective in the management of high-risk pediatric cancers?

2 Answers available

What are the perceived implications of broader genomic sequencing as it pertains to interpreting variants of unknown significance and germline predisposition mutations?

Increased genomic testing is likely to increase the frequency with which we encounter these mutations, which we might not otherwise have tested for. H...

3 Answers available

What is your current practice around genomic sequencing for pediatric cancers?

Do you plan to change your practice based on the data presented in this JCO paper by Summers et al?

1 Answer available